Antigen p64K hVEGFKDR adjuvant NAcGM3 VSSP
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameAntigen p64K hVEGFKDR adjuvant NAcGM3 VSSP
Drug Alias Name +[7]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCenter For Genetic Engineering And Biotechnology
China Registration ClassN/A
Develop Information
Active CompaniesHeberCenter For Genetic Engineering And Biotechnology
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A